



Significant Shareholder Disclosure

For Immediate Release:

March 9, 2016

Sydney, Australia – Simavita Limited (ASX: SVA; TSX-V: SV) (“Simavita” or the “Company”) advises that pursuant to ASX Listing Rule 3.17.3 and following the Company’s recent placement, the Company provides the attached significant shareholder disclosure that was lodged in Canada in accordance with the *Securities Act* (British Columbia) and applicable national instruments and policies.

For further information, see our website (www.simavita.com) or contact the persons outlined below.

Company	Media and Investor Relations
Philippa Lewis, Chief Executive Officer T: +61 2 8405 6381	Glen Zurcher E: glen.zurcher@irdepartment.com.au T: +61 420 249 299

About Simavita

Simavita is a digital healthcare company that has developed an innovative software platform. The first application for the platform is a world first solution for the management of urinary incontinence, with a focus on the elderly. This platform technology is an instrumented incontinence assessment application that provides evidence-based incontinence management care plans to the residential aged care market.

About SIM®

SIM® is a wireless sensor technology that delivers evidence-based instrument incontinence data on individuals. SIM® provides user friendly tools and software to assess the incontinence condition and to help plan better outcomes. SIM® is used to detect, record and report incontinence events during a compulsory or recommended assessment period in residential aged care facilities to develop an evidence-based incontinence care plan.

Conducting assessments is mandatory in many countries and the incontinence assessment creates an influential element of care of each individual. For more information on Simavita or SIM®, please visit www.simavita.com.

The TSX Venture Exchange has in no way passed upon the merits of the transactions set out herein and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this Release.

DUSSMAN PTY LTD. ACQUIRES CHESS DEPOSITARY INTERESTS AND PLACEMENT OPTIONS OF SIMAVITA LIMITED

Melbourne, Australia, March 4, 2016 – On March 2, 2016, Dussman Pty Ltd. (“Dussman”), as trustee for Devonian Investment Trust, the Charolais Superannuation Fund, the Charolais Super Fund No. 2, and the Charolais Super Fund No. 3, acquired 6,666,667 Chess Depositary Interests (“CDIs”) to be issued by CHESSE Depositary Nominees Pty Limited and 1,333,333 unlisted options (“Placement Options”) which are issued on the basis of one attaching Placement Option for every five CDIs issued. Each CDI represents an interest in a corresponding common share (the “Shares”) in the capital of Simavita Limited (“Simavita”) at an issue price of AUD\$0.15 per CDI. Each Placement Option entitles the Offeror to acquire one CDI/Share in Simavita at an exercise price of AUD\$0.15 on or before March 2, 2017.

The CDIs and Placement Options were acquired by way of a private placement offering. Dussman acquired the CDIs and Placement Options for investment purposes only.

Dussman now controls Shares and CDIs in the capital of Simavita representing approximately 35.90% of the outstanding Shares and CDIs of Simavita. Dussman owns and controls 1,256,145 Shares on its own behalf. The remaining Shares and CDIs are held by Dussman as trustee as follows: 23,437,175 Shares and CDIs as trustee for Devonian Investment Trust (14,024,295 Shares and 9,412,880 CDIs); 1,799,049 Shares as trustee for Devonian Trust No. 2; 1,753,677 Shares and CDIs as trustee for the Charolais Super Fund No. 2 (687,010 Shares and 1,066,667 CDIs); 897,561 Shares and CDIs as trustee for the Charolais Super Fund No. 3 (97,561 Shares and 800,000 CDIs); and 8,245,010 Shares as trustee for The Charolais Superannuation Fund (6,445,010 Shares and 1,800,000 CDIs).

Dussman may be considered a joint actor with Damien Haakman and Justin Haakman, both of whom are directors and shareholders of Dussman. Damien Haakman owns and controls 5,000 Shares on his own behalf and holds 380,757 Shares as trustee for The DMH Trust. Justin Haakman owns and controls 5,000 CDIs on his own behalf and holds 380,757 CDIs as trustee for The JAH Trust. Damien Haakman and Justin Haakman acquired the beforementioned Shares at a deemed price of \$0.41 per Share pursuant to the acquisition by Simavita (formerly named Gtech International Resources Limited) of all of the issued and outstanding shares of Simavita Holdings Limited pursuant to a scheme of arrangement under Australian law involving the shareholders of Simavita Holdings Limited that occurred in December 2013. In aggregate, Dussman, Damien Haakman and Justin Haakman hold 38,160,131 Shares and CDIs representing 36.64% of the outstanding Shares and CDIs of Simavita.

The acquisition of Shares was effected pursuant to a private placement and Dussman entered into a subscription agreement with Simavita in connection with the acquisition of the CDIs and Placement Options and such subscription agreement contained representations, warranties and covenants of the respective parties that are standard and customary in agreements of this nature, including representations that allow reliance of applicable Canadian private placement exemptions.

For further information, or a copy of the early warning report filed in respect of the above, please see the contact information below.

Dussman Pty Ltd.
Damien Haakman, Director
42 Halcyon Way
Narre Warren South
Melbourne, Victoria 3805
Australia
Tel: +613 9555 3077

**EARLY WARNING REPORT PURSUANT TO
NATIONAL INSTRUMENT 62-103**

1. Name and Address of Offeror:

Dussman Pty Ltd. (the "Offeror")
42 Halcyon Way
Narre Warren South
Melbourne, Victoria 3805
Australia

2. Designation and number or principal amount of securities and the Offeror's securityholding percentage in the class of securities which the Offeror acquired ownership or control in the transaction or occurrence giving rise to the obligation to file the news release, and whether it was ownership or control that was acquired in those circumstances:

On March 2, 2016, the Offeror, as trustee for Devonia Investment Trust, the Charolais Superannuation Fund, the Charolais Super Fund No. 2, and the Charolais Super Fund No. 3, acquired 6,666,667 Chess Depository Interests ("CDIs") to be issued by CHESS Depository Nominees Pty Limited and 1,333,333 unlisted options ("Placement Options") which are issued on the basis of one attaching Placement Option for every five CDIs issued. Each CDI represents an interest in a corresponding common share (the "Shares") in the capital of Simavita Limited ("Simavita") at an issue price of \$0.15 Australian Dollars per CDI. Each Placement Option entitles the Offeror to acquire one CDI/Share in Simavita at an exercise price of \$0.15 Australian Dollar on or before March 2, 2017.

The Offeror now controls Shares and CDIs in the capital of Simavita representing approximately 35.90% of the outstanding Shares and CDIs of Simavita. The Offeror owns and controls 1,256,145 Shares on its own behalf and as trustee as follows: 23,437,175 Shares and CDIs as trustee for Devonia Investment Trust (14,024,295 Shares and 9,412,880 CDIs); 1,799,049 Shares as trustee for Devonia Trust No. 2; 1,753,677 Shares and CDIs as trustee for the Charolais Super Fund No. 2 (687,010 Shares and 1,066,667 CDIs); 897,561 Shares and CDIs as trustee for the Charolais Super Fund No. 3 (97,561 Shares and 800,000 CDIs); and 8,245,010 Shares as trustee for The Charolais Superannuation Fund (6,445,010 Shares and 1,800,000 CDIs).

The Offeror may be considered a joint actor with Damien Haakman and Justin Haakman, both of whom are directors and shareholders of the Offeror. Damien Haakman owns and controls 5,000 Shares on his own behalf and holds 380,757 Shares as trustee for The DMH Trust. Justin Haakman owns and controls 5,000 CDIs on his own behalf and holds 380,757 CDIs as trustee for The JAH Trust. Damien Haakman and Justin Haakman acquired the beforementioned Shares at a deemed price of \$0.41 Australian Dollars per Share pursuant to the acquisition by Simavita (formerly named Gtech International Resources Limited) of all of the issued and outstanding shares of Simavita Holdings Limited pursuant to a scheme of arrangement under Australian law involving the shareholders of Simavita Holdings Limited that occurred in December 2013.

In aggregate, the Offeror, Damien Haakman and Justin Haakman hold 38,160,131 Shares and CDIs representing 36.64% of the outstanding Shares and CDIs of Simavita.

3. Designation and number or principal amount of securities and the Offeror's securityholding percentage in the class of securities immediately after the transaction or occurrence giving rise to the reporting obligation:

The Offeror now holds 37,388,617 Shares and CDIs in the capital of Simavita representing approximately 35.90% of the outstanding Shares and CDIs of Simavita. Damien Haakman now holds 385,757 Shares in the capital of Simavita representing approximately 0.4% of the outstanding Shares and CDIs of Simavita. Justin Haakman now holds 385,757 Shares in the capital of Simavita representing approximately 0.4% of the outstanding Shares and CDIs of Simavita. In aggregate, the Offeror, Damien Haakman and Justin Haakman hold 38,160,131 Shares and CDIs in the capital of Simavita representing approximately 36.64% of the outstanding Shares and CDIs of Simavita.

The Offeror now holds 1,333,333 Placement Options which are exercisable into one CDI/Share at a price of \$0.15 Australian Dollar. The Offeror holds the Placement Options as trustee as follows: 666,667 Placement

Options as trustee for Devonia Investment Trust; 360,000 Placement Options as trustee for the Charolais Superannuation Fund; 173,333 Placement Options as trustee for the Charolais Super Fund No. 2; and 133,333 Placement Options as trustee for the Charolais Super Fund No. 3.

4. Designation and number or principal amount of securities and the percentage of outstanding securities of the class of securities referred to in paragraph 3 over which:

(a) The Offeror, either alone or together with any joint actors, has ownership and control:

The Offeror, without including such entities in which the Offeror acts as trustees, has beneficial ownership and control over 1,256,145 Shares/CDIs. Damien Haakman has beneficial ownership and control over 5,000 Shares. Justin Haakman has beneficial ownership and control over 5,000 CDIs. In aggregate, the Offeror, Damien Haakman and Justin Haakman beneficially own and control 1,266,145 Shares/CDIs representing 1.2% of the outstanding Shares of Simavita.

(b) The Offeror, either alone or together with any joint actors, has ownership but control is held by other persons or companies other than the Offeror or any joint actor:

No applicable.

(c) The Offeror, either alone or together with any joint actors, has exclusive or shares control but does not have ownership:

The Offeror holds Shares and CDIs as trustee as follows: 23,437,175 Shares and CDIs as trustee for Devonia Investment Trust (14,024,295 Shares and 9,412,880 CDIs); 1,799,049 Shares as trustee for Devonia Trust No. 2; 1,753,677 Shares and CDIs as trustee for the Charolais Super Fund No. 2 (687,010 Shares and 1,066,667 CDIs); 897,561 Shares and CDIs as trustee for the Charolais Super Fund No. 3 (97,561 Shares and 800,000 CDIs); and 8,245,010 Shares as trustee for The Charolais Superannuation Fund (6,445,010 Shares and 1,800,000 CDIs). Damien Haakman holds 380,757 Shares as trustee for The DMH Trust. Justin Haakman holds 380,757 CDIs as trustee for The JAH Trust. In aggregate, the Offeror, Damien Haakman and Justin Haakman hold 38,160,131 Shares and CDIs in the capital of Simavita representing approximately 36.64% of the outstanding Shares and CDIs of Simavita.

Further, the Offeror holds Placement Options as trustee as follows: 666,667 Placement Options as trustee for Devonia Investment Trust; 360,000 Placement Options as trustee for the Charolais Superannuation Fund; 173,333 Placement Options as trustee for the Charolais Super Fund No. 2; and 133,333 Placement Options as trustee for the Charolais Super Fund No. 3.

5. The name of the market in which the transaction or occurrence that gave rise to the reporting obligation took place:

Not applicable.

6. The value, in Canadian dollars, of any consideration offered per security if the Offeror acquired ownership of a security in the transaction or occurrence giving rise to the obligation to file a news release:

The Offeror acquired the CDIs and Placement Options disclosed herein at an issue price of \$0.15 Australian Dollars per CDI, which is approximately equal to \$0.15 Canadian dollars at a conversion rate of 0.99.

7. Purpose of the Offeror and any joint actors in effecting the transaction or occurrence that gave rise to the reporting obligation, including any future intention to acquire ownership of, or control over, additional securities of the issuer:

The Offeror acquired the CDIs and Placement Options for investment purposes. The Offeror may acquire additional ownership or control over Shares or CDIs or Placement Options in the future.

8. General nature and the material terms of any agreement, other than lending arrangements, with respect to the securities of the reporting issuer entered into by the Offeror, or any joint actor, and the issuer of the securities or any other entity in connection with the transaction or occurrence giving rise

to the reporting obligation, including agreements with respect to the acquisition, holding, disposition or voting of any of the securities:

Not applicable.

9. Names of any joint actor in connection with the disclosure required herein:

The Offeror may be considered a joint actor with Damien Haakman and Justin Haakman.

10. In the case of a transaction or occurrence that did not take place on a stock exchange or other market that represents a published market for the securities, including an issuance from treasury, the nature and value of the consideration paid by the Offeror:

The CDIs and Placement Options were acquired at a purchase price of \$0.15 Australian Dollars per CDI.

11. If applicable, a description of any change in any material fact set out in the previous report by the entity under the early warning requirements of Part 4 of National Instrument 62-103 in respect of the reporting issuer's securities:

Not applicable.

12. If applicable, a description of the exemption from securities legislation being relied on by the Offeror and the facts supporting that reliance:

Simavita understands that the Offeror relied on the exemption under British Columbia Instrument 72-503 (distribution of securities outside British Columbia) in acquiring the aforementioned CDIs and is exempt under National Instrument 45-106 – *Prospectus and Registration Exemptions*, based on a representation made by the Offeror as to its accredited investor status.

DATED this 4th day of March, 2016.